|
A Look
at the Charts
Clearly Canadian (CCBEF) has been in an uptrend
since it closed at $2.75 to it's current close of $3.17. The
short, mid and long term technicals are all currently giving
bullish signals. This break out has been on above average
volume and the corresponding support level has risen also.
CCBEF should definitely be on your radar, if not in your
portfolio in the coming days.
Web2Corp (WBTO) has had similar success
breaking out on strong volume from an intraday low of $1.45
on 2/22 to close at $1.71 yesterday.
Monogram Biosciences (MGRM) had been in a
$1.95 to $2.00 trading range and has recently broke out to the
upside for a strong bullish 3 day chart pattern. The company
announced earlier this month that its collaborator Pfizer, has
said that the U.S. Food and Drug Administration (FDA) has
granted priority review status and the European Medicines
Agency (EMEA) has agreed to the accelerated review procedure
for the marketing authorization applications for Maraviroc.
You can learn more about Monogram Biosciences here.
Clearly
Canadian (CCBEF)
Website:
www.clearly.ca
Press
Release: Clearly
Canadian Announces New U.S. Mid West Distributors
Announced
that it continues to expand its North American distribution
network with the appointment of three new U.S. Mid West
distributors of Clearly Canadian products. Joining the fast
growing list of top quality distributors already announced by
the Company is DTM Distributing Inc., covering the greater
Minneapolis/St. Paul area. And, to cover the majority of
Missouri, the Company has also appointed Folsom Distributing
Company for St. Louis and surrounding area, and Palmentere
Brothers Distributing Company for the greater Kansas City
area.
To
learn more about Clearly Canadian Click
Here.
For
the latest News and Quotes on CCBEF Click
Here.
Monogram
Biosciences (MGRM)
Website:
www.monogrambio.com
"Pfizer
plans to offer Marovirac alongside a test developed by
Monogram Biosciences Inc. that gauges whether patients are
likely to respond to the treatment."
To
learn more about Monogram Biosciences Click
Here.
For
the latest News and Quotes on MGRM Click
Here.
Overview
Monogram
Biosciences (MGRM) advances
individualized medicine by developing and marketing
innovative products to help guide and improve the
treatment of infectious diseases and cancer. Products are
designed to help healthcare providers and pharmaceutical
companies select and monitor patients to optimize
treatment regimens and develop new and improved antiviral
and targeted cancer therapeutics.
The company's products for
infectious diseases include PhenoSense HIV that directly
and quantitatively measures resistance of a patient's HIV
to anti-viral drugs; GeneSeq HIV for examining and
evaluating the genetic sequences of a patient's HIV;
PhenoSense GT; Replication Capacity HIV that measures
viral fitness or the ability of a virus to reproduce and
infect new cells; PhenoScreen for the identification of
potential clinical drug candidates; and PhenoSense HIV
Entry that measures resistance of a patient's HIV to entry
inhibitors.
It also offers GeneSeq HIV
Entry, which examines and evaluates the genetic sequences
of a patient's HIV for evidence of resistance to entry
inhibitors; Co-Receptor Tropism that identifies the
co-receptor the patient's virus uses to enter cells;
PhenoSense and GeneSeq HIV Integrase that measures HIV
resistance to integrase inhibitors for use in research and
drug development; and PhenoSense HIV Antibody
Neutralization for use in vaccine development programs. In
addition, the company offers PhenoSense HCV and GeneSeq
HCV assays for use in their drug discovery and development
programs by pharmaceutical companies.
Monogram Biosciences also
provides eTag technology, an assay platform for analyzing
very small amounts of tumor samples recovered and prepared
in various methods, for use in cancer therapeutics. The
company offers its products to physicians and
pharmaceutical customers through a direct and indirect
sales organization.
MGRM
Investor Highlights
- MGRM's collaborator
Pfizer (NYSE: PFE) has announced that the U.S. Food
and Drug Administration (FDA) has granted priority
review status and the European Medicines Agency (EMEA)
has agreed to the accelerated review procedure for the
marketing authorization applications for maraviroc,
potentially the first in a new class of HIV
treatments. Pfizer submitted the U.S. and EU
applications in December 2006 for maraviroc as
treatment for antiretroviral-experienced patients with
a specific strain of HIV (CCR5-tropic HIV-1).
- Monogram's co-receptor
tropism assay, Trofile(TM), was used for patient
selection for Maraviroc's clinical development
program, and the two companies are engaged in a
collaboration agreement to make Monogram's assay
available for patient use on a global basis.
"Throughout the clinical development of maraviroc,
physicians and patients relied on Trofile to predict a
patient's likelihood for response," said Monogram
CEO William Young. "We believe this new model of
drug and diagnostic collaborations will create a more
personalized and effective treatment for patients with
HIV."
- Maraviroc is designed to
work differently from other available HIV medications.
CCR5 antagonists block the virus from gaining access
into healthy cells via the CCR5 co-receptor, a common
pathway for viral entry. Monogram's Trofile
co-receptor tropism assay identifies whether
individual strains of HIV use the CCR5 co-receptor,
the CXCR4 co-receptor or both co- receptors to infect
healthy cells. This helps clinicians determine whether
a CCR5 antagonist like maraviroc may be a good
therapeutic option for treating individual patients.
Pfizer expects to present the results of a phase III
study of maraviroc at an upcoming scientific meeting.
- Maraviroc and other
entry inhibitors currently in development come at a
time when increasing drug resistance makes treating
HIV more difficult than ever. Highly sensitive and
precise diagnostic tools are playing an ever more
important role in the development of new therapeutic
approaches that give new hope to physicians and
patients running low on options.
- A Food and Drug
Administration panel in April will review a Pfizer HIV
therapy that, if approved, would be the first in a new
class of drugs to treat the virus that causes AIDS.
The FDA said its antiviral drugs advisory committee
will meet April 24 to assess the safety and
effectiveness of Pfizer's Maraviroc. Pfizer plans to
offer the drug alongside a test developed by Monogram
Biosciences Inc. that gauges whether patients are
likely to respond to the treatment.
To
learn more about Monogram Biosciences Click
Here.
Web2
Corp (WBTO) Website:
www.web2corp.com
Press
Release:
Web2Corp
Paves Web 2.0 Road for Chambers of Commerce Nationwide Out
of the Internet's Billion Users, 95% Are Unable to Publish
Online Media; ChamberECommerce.com Allows Users of All
Levels to Transition Their Existing Business or Develop
New Online Businesses Instantly To
learn more about Web2Corp Click
Here.
For
the latest News and Quotes on WBTO Click
Here.
News
From the Site
Where
to Next... The blue
chip indexes paused last week while the Nasdaq played some
catch-up, finally breaking out to a new recovery high.
Small- and mid-cap stocks made new all-time highs.
Making
the small fries count in a big way...
A
fabulous 56.72 per cent (as on February 20, 2007) return
since its launch in October 2004, that too on the back of
mid- and smal-cap holdings, is what caught our attention.
Consumer
Spending Growth Likely to Remain Strong as Customer
Satisfaction Hits All Time High...
Patience
and homework can pay off on small caps...
SmallCapReview.com
feature stock reports are intended to be stock ideas,
NOT recommendations. Please do your own research before
investing. It is crucial that you at least look at
current SEC filings and read the latest press
releases. For continuing coverage of CCBEF, WBTO and
MGRM please sign
up for our free newsletter. Information contained in
this report was extracted from current documents filed
with the SEC, the company web site and other publicly
available sources deemed reliable. For more information
see our disclaimer section, a link of which can be found
on our web site. This document contains forward-looking
statements, particularly as related to the business
plans of the Company, within the meaning of Section 27A
of the Securities Act of 1933 and Sections 21E of the
Securities Exchange Act of 1934, and are subject to the
safe harbor created by these sections. Actual results
may differ materially from the Company's expectations
and estimates. The information provided in this report
is not intended for distribution to, or use by, any
person or entity in any jurisdiction or country where
such distribution or use would be contrary to law or
regulation or which would subject us to any registration
requirement within such jurisdiction or country.
Copyright
SmallCapReview.com. All rights reserved.
SmallCapReview.com is not a Registered Broker/Dealer or
Financial Advisor, nor do we hold ourselves out to be.
All materials presented on our web site and individual
reports released to the public through this web site,
e-mail or any other means of transmission are not to be
regarded as investment advice and are only for
informative purposes. Before making a purchase or sale
of any securities featured on our web site or
mentioned in our reports, we strongly encourage and
recommend consultation with a registered securities
representative. This is not to be construed as a
solicitation or recommendation to buy or sell
securities. As with any stock, companies we select to
profile involve a degree of investment risk and
volatility. Particularly Small-Caps and OTC-BB stocks.
All investors are cautioned that they may lose all or a
portion of their investment if they decide to make a
purchase in any of our profiled companies. Past
performance of our profiled stocks is not indicative of
future results. The accuracy or completeness of the
information on our web site or within our reports is
only as reliable as the sources they were obtained from.
The profile and opinions expressed herein are expressed
as of the date the profile is posted on site and are
subject to change without notice. No investor should
assume that reliance on the views, opinions or
recommendations contained herein will produce profitable
results. SmallCapReview.com may hold positions in
securities mentioned herein, and may make purchases or
sales in such securities featured on our web site or
within our reports. In order to be in full compliance
with the Securities Act of 1933, Section 17(b),
SmallCapReview.com will disclose in it's disclaimer,
what, if any compensation was received for our
efforts in researching, presenting and disseminating
this information to our subscriber database and
featuring the report on the SmallCapReview.com web site.
SmallCapReview.com
has been compensated thirty thousand dollars by the
Company and was previously compensated seventeen
thousand dollars by Level 3 Research for its efforts in
presenting the Clearly Canadian Beverage Corporation
profile on its website and distributing it to its
database of subscribers.
SmallCapReview.com has been compensated nine thousand
dollars by a third party (XSellmarketing) for its
efforts in presenting the WBTO profile on its website
and distributing it to its database of subscribers.
SmallCapReview.com has not been compensated for its
efforts in presenting the Monogram Biosciences profile on its website
and distributing it to its database of subscribers. SmallCapReview.com may decide to purchase
or sell shares on a voluntary basis in the open market
before, during or after the profiling period of this
report.
THE
READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE
DILIGENCE BEFORE INVESTING IN ANY SECURITIES
MENTIONED. INVESTING IN SMALL CAP SECURITIES IS
SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
We
encourage our readers to invest carefully and read the
investor information available at the web sites of the
Securities and Exchange Commission (SEC) at: http://www.sec.gov
and/or the National Association of Securities Dealers
(NASD) at: http://www.nasd.com. Readers can review all public filings by companies
at the SEC's EDGAR page. The NASD has published
information on how to invest carefully at its web site.
|
